Guggenheim Initiates Coverage of Immunic with Buy Rating, Stock Price Rises

LootboxPhobia · 2026-03-25T01:16:46+00:00

Immunic Inc. stock rose 7.7% after a Guggenheim analyst issued an initial buy rating with a $7 price target. The company is developing an oral multiple sclerosis drug and will release Phase III trial data by end of 2026, with significant projected global sales.

LootboxPhobia

2026-03-25 01:16:46

Abstract generation in progress

Investing.com – Immunic Inc. (NASDAQ:IMUX) stock rose 7.7% on Tuesday after Guggenheim analyst Yatin Suneja initiated coverage with a buy rating and a target price of $7.00.

The company is developing vidofludimus calcium, an oral therapy for multiple sclerosis aimed at relapsing and progressive MS patients, addressing relapse-related worsening and disease progression independent of relapse activity.

Suneja noted that the candidate drug is supported by two Phase II studies involving 268 relapsing MS patients and 467 progressive MS patients. The studies showed the drug reduced relapse risk and controlled disability levels. The analyst emphasized that vidofludimus calcium maintains a safety profile similar to placebo, with no liver toxicity, infections, or monitoring burden.

Guggenheim expects the primary data from the Phase III ENSURE study for relapsing MS to be released by the end of 2026, with about 1,100 patients in each trial. Results from the Phase III study for primary progressive MS are expected around 2030.

The analyst estimates global peak sales for relapsing MS at approximately $1 billion with a 75% probability of success; for primary progressive MS, peak sales are estimated at about $2 billion with a 60% success probability. Immunic’s current fully diluted market cap is approximately $800 million.

This article was translated with AI assistance. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.